4 completed, 4 recruiting, 2 not yet recruiting, 2 terminated. 3 Not applicable, 2 Phase 1, 2 Phase 2, 2 Phase 3, 1 Phase 4.
Follow Drug Induced Liver Injury: new trials by email Literature Review of Drug Induced Liver Injury trials Research Report on Drug Induced Liver Injury
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Comparison of the Outcome of Treatment With Silymarin or N-Aceylcysteine in Patients Taking Anti-Tuberculous Drugs for Tuberculosis at a Tertiary Care Hospital , Karachi Silymarin 420 mg, N Acetyl Cysteine, Rifampicin (RMP) Ethambutol (E) Isoniazid (H) Pyrazinamid (Z) - Drug Induced Liver Injury, Tuberculosis (TB) | Phase 1 | Not yet recruiting | Liaquat National Hospital & Medical College | 410 | 2025-07-01 | 2025-07-10 |
| Drug-induced Liver Injury: Itching Study Drug Induced Liver Injury, Pruritus | Recruiting | University of Nottingham | 50 | 2025-06-30 | 2026-07-27 | |
| Glucocorticoids for Acute Drug Induced Liver Injury With Hyperbilirubinemia Methylprednisolone, Magnesium isoglycyrrhizinate, Glutathione - Drug Induced Liver Injury | Not applicable | Recruiting | General Hospital of Shenyang Military Region | 232 | 2025-06-24 | 2025-12-18 |
| Efficacy of Plasmapheresis in Patients of Drug-Induced Liver Injury (DILI) With Underlying Chronic Liver Disease High volume Plasma Exchange, Standard Medical Treatment - Drug Induced Liver Injury, Chronic Liver Disease | Phase 2 / Phase 3 | Not yet recruiting | Institute of Liver and Biliary Sciences, India | 96 | 2025-01-25 | 2025-01-28 |
| Clinical Study to Evaluate Cannabidiol Liver Enzyme Elevations and Drug Interactions Cannabidiol, Placebo, Citalopram - Cannabidiol, Drug Induced Liver Injury | Phase 1 | Completed | Food and Drug Administration (FDA) | 241 | 2024-02-08 | 2025-07-31 |
| Prospective Comparative Validation Study of RUCAM and RECAM Drug Induced Liver Injury | Recruiting | Beijing Friendship Hospital | 407 | 2023-05-01 | 2025-01-13 | |
| Efficacy of N-acetylcysteine to Prevent Anti-tuberculosis Drug-induced Liver Injury: A Randomized Controlled Trial N acetyl cysteine - Tuberculosis, Drug Induced Liver Injury | Phase 2 / Phase 3 | Unknown | Mahidol University | 82 | 2022-09-09 | 2023-02-22 |
| Remaxol® in Patients With Drug-induced Liver Injuries During Cancer Chemotherapy Remaxol - Cancer, Drug Induced Liver Injury | Completed | POLYSAN Scientific & Technological Pharmaceutical Company | 368 | 2022-05-12 | 2025-08-13 | |
| A Multicenter Observational Study on Safety of the Herbal Medicines at Inpatient Setting Drug Induced Liver Injury, Drug-Induced Kidney Injury | Terminated | Korea Institute of Oriental Medicine | 287 | 2019-07-01 | 2025-09-03 | |
| Efficacy of N-acetylcysteine With or Without Steroids in Drug Induced Liver Injury Prednisolone, N-Acetylcysteine - Drug Induced Liver Injury | Not applicable | Terminated | Institute of Liver and Biliary Sciences, India | 4 | 2016-03-01 | 2017-12-18 |
| Identifying Changes in Blood (Potential Biomarkers) in Individuals With Drug-Induced Liver Injury Drug Induced Liver Injury | Completed | University of North Carolina, Chapel Hill | 25 | 2009-09-01 | 2017-04-18 | |
| Acetaminophen in Combination With N-Acetylcysteine (NAC) Versus Placebo in Treating Fever APAP and NAC combination, APAP and Placebo - Liver Failure, Liver Failure, Acute | Not applicable | Withdrawn | Columbia University | 2009-04-01 | 2015-03-05 | |
| Acetaminophen Adduct Formation in Non-Drinkers Taking Therapeutic Doses of Acetaminophen for Ten Consecutive Days acetaminophen - Drug Induced Liver Injury | Phase 4 | Completed | Kennon Heard | 35 | 2007-08-01 | 2012-07-12 |
| Drug-Induced Liver Injury (DILI) Network Retrospective Drug Induced Liver Injury | Recruiting | Duke University | 400 | 2004-09-01 | 2026-04-08 |
Chemical and Drug Induced Liver Injury (14) · Liver Failure (2) · Tuberculosis (2) · Fever (1) · Hepatitis (1) · Hyperbilirubinemia (1) · Liver Failure, Acute (1) · Neoplasms (1) · Pruritus (1)
Chemically-Induced Disorders (14) · Digestive System Diseases (14) · Drug-Related Side Effects and Adverse Reactions (14) · Liver Diseases (14) · Poisoning (14) · Pathological Conditions, Signs and Symptoms (3) · Actinomycetales Infections (2) · Bacterial Infections (2) · Bacterial Infections and Mycoses (2) · Gram-Positive Bacterial Infections (2) · Hepatic Insufficiency (2) · Infections (2) · Mycobacterium Infections (2) · Signs and Symptoms (2) · Body Temperature Changes (1)
Acetylcysteine (4) · Acetaminophen (2) · Silymarin (2) · 18alpha,20beta-hydroxy-11-oxo-norolean-12-en-3beta-yl-2-O-beta-D-glucopyranurosyl-alpha-D-glucopyranosiduronate magnesium tetrahydrate (1) · Cannabidiol (1) · Citalopram (1) · Ethambutol (1) · Glutathione (1) · Isoniazid (1) · Liver Transplantation (1) · Methylprednisolone (1) · Morphine (1) · Prednisolone (1) · Protons (1) · Pyrazinamide (1)
Institute of Liver and Biliary Sciences, India (2) · Beijing Friendship Hospital (1) · Columbia University (1) · Duke University (1) · Food and Drug Administration (FDA) (1) · General Hospital of Shenyang Military Region (1) · Kennon Heard (1) · Korea Institute of Oriental Medicine (1) · Liaquat National Hospital & Medical College (1) · Mahidol University (1) · POLYSAN Scientific & Technological Pharmaceutical Company (1) · University of North Carolina, Chapel Hill (1) · University of Nottingham (1)
United States (5) · China (2) · India (2) · Russia (1) · South Korea (1) · Thailand (1) · United Kingdom (1)
Ariba Sultan (1) · Dal-Seok Oh, OMD, PhD (1) · Dr Anand Kulkarni V, MD (1) · Fengmei Wang (1) · Huiman X. Barnhart, PhD (1) · Kennon Heard, MD (1) · Lu Zhou (1) · Matthew Chang, MD (1) · Melanie Fein, MD (1) · Paul B Watkins, MD (1) · Qing Ye (1) · Robert Fontana, MD (1) · Supot Nimanong, MD (1) · Weifen Xie (1) · Xin Zeng (1)
PMID 22806342, PMID 26400476, PMID 27426618, PMID 38402364, PMID 39183394, PMID 40622698, PMID 42080196, PMID 42684112
U01DK065176 (1)